A Nuclear Magnetic Resonance Spectroscopy as a Method for Evaluation of In Vivo Poly-l-Lactide Biodegradation Kinetics From Stent-Polymer Matrices

Abstract

The utilization of NMR method for BP absorption kinetics evaluation is a useful tool, which may be widely adopted to test other biodegradable implants. Further, it may substantially improve their safety and efficacy by facilitating programmed polymer and drugs elution.

First-in-man study of dedicated bifurcation cobalt-chromium sirolimus-eluting stent BiOSS LIM C® — three-month results

“…1) [17]. The degradation of the polymer lasts approximately eight weeks [18]. The BiOSS LIM C ® stent consists of two main separate parts with different diameters: wider proximally, and distally smaller.…”

Comparable vascular response of a new generation sirolimus eluting stents when compared to fluoropolymer everolimus eluting stents in the porcine coronary restenosis model

“…The total mass of the polymer on a 3.0 × 15 mm stent does not exceed 360 μg. The experimental studies in the porcine in-stent restenosis model at 8 weeks has shown nearly full polymer biodegradation and 95% drug release of initial drug load [12]. The stent utilizes the L605 cobalt chromium alloy platform with strut thickness of 70 μm and closed cell design, which also served as bare metal control (BMS, Coflexus, Balton).…”

Bioresorbable polymer‐coated thin strut sirolimus‐eluting stent vs durable polymer‐coated everolimus‐eluting stent in daily clinical practice: Propensity matched one‐year results from interventional cardiology network registry

“…The total mass of the polymer on a 3.0 × 15 mm stent does not exceed 360 μg. Experimental studies in the porcine in‐stent restenosis model at 8 weeks showed nearly full polymer biodegradation and 95% drug release of initial drug load . In the previously published study, BP‐SES demonstrated favorable performance in complex coronary lesions of 424 patients in daily clinical practice .…”

“…Experimental studies in the porcine in-stent restenosis model at 8 weeks showed nearly full polymer biodegradation and 95% drug release of initial drug load. 13 In the previously published study, BP-SES demonstrated favorable performance in complex coronary lesions of 424 patients in daily clinical practice. 14 BP-SES displayed high clinical device success (98.5%), and acute gain (1.67 AE 0.44 mm) together with low residual diameter stenosis (6.43 AE 4.16%).…”